Write to Win (Round 9): Which invention from the past decade would you erase from existence?
Our writing contest starts with 10 students, who are eliminated one at a time based on your votes and YP editors’ picks.
Pharmaceutical Technology1d
NHS England to offer Casgevy for sickle cell disease patients
The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...
Le Lézard2d
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
Vertex Pharmaceuticals announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene ...
GEN3d
Epigenetic Chromosomal State Remains Stable in Plants after Inversion by CRISPR/Cas Technology
Results prove that inversions can be generated in plants without causing further unwanted changes in the expression of genetic information.
Taiwan News3d
CRISPR Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference
A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...
Fintel on MSN5d
Morgan Stanley Downgrades Intellia Therapeutics (NTLA)
Fintel reports that on January 27, 2025, Morgan Stanley downgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 449.14% ...